The Current Value of the Global Peptide Therapeutics Market

"The number of companies specializing in the manufacture of therapeutic peptides has been shrinking over the last 15 years with fewer new companies entering the market than those leaving it."  

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA. 


In this interview, Dr. Lax discusses:

• - The current estimated value of the global peptide therapeutics market.
• - The key factors that contribute to the constant growth of the global peptide therapeutics market.
• - The advantages/disadvantages to a consolidated peptide manufacturing industry.
• - Which emerging markets are leading the forefront of peptide therapeutics research and development
• - Opportunities that are emerging due to recent advancements in manufacturing and delivery technology

 Access the complete interview here.

PLUS! As a blog reader, you are eligible to save $300 when registering for TIDES. Use the code B16180BLOG100 to activate your savings. Click here to register.

Share this article with your social network, just click below to share now!

Share |

Evaluating the Oligo and Peptide Market and Investment Landscape

The global oligonucleotide and peptide therapeutic market is experiencing rapid growth due to the constant development of new technologies, emerging markets and novel drug classes. Stay at the forefront of global investments, deals and developments in the oligonucleotide and peptide market by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

Industry Experts Provide Updates on the Oligonucleotide and Peptide Market and Investment Landscape: 

1. The Oligo Therapeutics Market Landscape – A 15 Year Retrospective on Market Trends, Deals, Investments, and Key Clinical Developments with a Look to the Future Gary Carter, Director of Strategy and Marketing, Nucleic Acid Solutions Division, Agilent Technologies, Inc. Over the last 15 years the number of oligo therapeutic programs has grown from roughly 100 programs in 2002 to almost 300 in 2015, driven by the emergence of new classes such as siRNA, miRNA, and exon-skipping therapeutics, coupled with corresponding increases in direct investment and deal values. Read full abstract here.

2. Redefining the Therapeutic Peptide Business in the 21st Century Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group The last 30 years has seen significant changes in our expectations for peptide therapeutics. While the peptide manufacturing industry has consolidated during that period, the complexity of the products themselves, the scale of manufacture, and number of potential delivery platforms have continually increased...(read full abstract here )

3. Personalized Medicine Patent Law Update Laura A. Labeots, Ph.D., J.D., Partner, Husch Blackwell Brief summary of Subject Matter Eligibility of patents based on natural products (35 USC 101) will be presented, along with discussion of practical implications of developing case law surrounding personalized medicine and nucleic acid diagnostics and therapeutics...(read full abstract here)

The #1 Meeting for Oligos and Peptides!

• 800+ attendees representing 25 countries help you forge new business and scientific collaborations;
• 100+ speaker presentations across 5 tracks provide a customized agenda of solutions for your company’s current challenges;
• 70+ exhibitors demonstrate the latest products and technologies to accelerate your therapeutic to market;
• 40+ poster presentations keep you abreast of cutting-edge industry and academic research

For full program details, download the TIDES 2016 brochure today!

Register by January 29 and Receive a $600 Savings! Use unique code B16180LINK100.

Best,
The TIDES 2016 Team

Visit the website.
Follow us on Twitter: @ibcusa #ibcTIDES
Read our blog: www.futurebiopharma.blogspot.com

Share this article with your social network, just click below to share now!

Share |

TIDES 2015 Speaker Deadline + Early Registration Offer

Few speaking slots remain at IBC's 17th Annual TIDES meeting, held on May 3-6, 2015 in San Diego, CA. If you are working in any of the following scientific areas below, we encourage you to submit a speaker proposal by Wednesday, November 5, 2014 for a podium presentation:

• -Oligonucleotide Manufacturing Technology, Analysis, CMC & Regulatory
• -Peptide Manufacturing Technology, Analysis, CMC & Regulatory
• -Oligonucleotide Discovery & Clinical Development
• -Peptide Discovery & Clinical Development

To see an in-depth look of what we’re looking for in each of these categories and submit a presentation proposal here,

Your abstract and presentation must describe scientific results and must not contain marketing or business development content. If you are interested in speaking but cannot make the November 5 deadline, please email Michael Keenan as soon as possible.

How else can you participate in TIDES 2015?

• - Early Registration Offer Ends January 23, 2015. Save up to $400 when you register.
• - Sponsorship/Exhibition Opportunities: Highlight your company's expertise to this global audience of oligonucleotide and peptide decision makers by becoming an event sponsor or exhibitor. Email Sherry Johnson at  reach her at 508-614-1451 for pricing and package options.

Have any other questions on this year’s event? Feel free to reach out to me at jpereira@iirusa.com.

Share this article with your social network, just click below to share now!

Share |